FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601471281> ?p ?o ?g. }

• W2601471281 endingPage "48374" @default.
• W2601471281 startingPage "48362" @default.
• W2601471281 abstract "// Yan Yang 1 , Wei Pan 2 , Xinyu Tang 1 , Shuqing Wu 3 and Xinchen Sun 1 1 Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 2 Department of Radiation Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China 3 Department of Radiation Oncology, The Affiliated Danyang Hospital of Nantong University, Nantong, China Correspondence to: Shuqing Wu, email: // Xinchen Sun, email: // Keywords : breast cancer, anastrozole, tamoxifen, meta-analysis Received : February 06, 2017 Accepted : March 04, 2017 Published : March 22, 2017 Abstract Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial. Therefore, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of anastrozole versus tamoxifen as adjuvant therapy in breast cancer. A systematic literature search of PubMed, Web of Science, Embase, and Cochrane library were performed to evaluate the survival benefits and toxicity profiles of patients with breast cancer who were treated with anastrozole or tamoxifen. The main outcome measures included disease-free survival (DFS), recurrence-free survival (RFS), overall survival (OS), overall response rate (ORR), and adverse events. Hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a fixed-effects model or random-effects model. Nine RCTs with a total of 15,300 patients met the inclusion criteria and were included in this meta-analysis. Pooled estimates suggested that, anastrozole was associated with a significantly improvement in DFS (HR=0.72, 95%CI: 0.55-0.94; P =0.016), and ORR (RR=1.21, 95% CI: 1.05-1.39; P =0.009) than tamoxifen. But it did not prolong OS (HR=0.96, 95%CI: 0.77-1.21; P =0.751). Compared with tamoxifen, anastrozole induced a higher incidence of arthralgia (RR=1.55, 95%CI: 1.20-1.99; P =0.001) and bone pain (RR=1.31, 95%CI: 1.05-1.62; P =0.015), as well as a lower incidence of vaginal bleeding (RR=0.51, 95%CI: 0.28-0.93; P =0.029), vaginal discharge (RR=0.31, 95%CI: 0.12-0.82; P =0.017), and thromboembolic events (RR=0.39, 95%CI: 0.28-0.55; P <0.001). Based on the current evidence, patients with breast cancer would benefit from the anastrozole treatment." @default.
• W2601471281 created "2017-04-07" @default.
• W2601471281 creator A5004713760 @default.
• W2601471281 creator A5036593151 @default.
• W2601471281 creator A5038304016 @default.
• W2601471281 creator A5059647160 @default.
• W2601471281 creator A5090607267 @default.
• W2601471281 date "2017-03-22" @default.
• W2601471281 modified "2023-10-17" @default.
• W2601471281 title "A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole<i>versus</i>tamoxifen for breast cancer" @default.
• W2601471281 cites W1453600927 @default.
• W2601471281 cites W1562190372 @default.
• W2601471281 cites W1810933484 @default.
• W2601471281 cites W1932574503 @default.
• W2601471281 cites W1961026612 @default.
• W2601471281 cites W1964435302 @default.
• W2601471281 cites W1967315119 @default.
• W2601471281 cites W1975256062 @default.
• W2601471281 cites W1985385254 @default.
• W2601471281 cites W1985875128 @default.
• W2601471281 cites W1990582579 @default.
• W2601471281 cites W2019203094 @default.
• W2601471281 cites W2032207130 @default.
• W2601471281 cites W2042870098 @default.
• W2601471281 cites W2067962131 @default.
• W2601471281 cites W2067962376 @default.
• W2601471281 cites W2088095316 @default.
• W2601471281 cites W2098036430 @default.
• W2601471281 cites W2098923148 @default.
• W2601471281 cites W2106787323 @default.
• W2601471281 cites W2107328434 @default.
• W2601471281 cites W2110190287 @default.
• W2601471281 cites W2110712889 @default.
• W2601471281 cites W2112414071 @default.
• W2601471281 cites W2112780046 @default.
• W2601471281 cites W2116902655 @default.
• W2601471281 cites W2125435699 @default.
• W2601471281 cites W2132846837 @default.
• W2601471281 cites W2138401856 @default.
• W2601471281 cites W2148096512 @default.
• W2601471281 cites W2150000105 @default.
• W2601471281 cites W2151447010 @default.
• W2601471281 cites W2157823046 @default.
• W2601471281 cites W2160976261 @default.
• W2601471281 cites W2165010366 @default.
• W2601471281 cites W2165037690 @default.
• W2601471281 cites W2167027232 @default.
• W2601471281 cites W2189712549 @default.
• W2601471281 cites W2191470295 @default.
• W2601471281 cites W2207029559 @default.
• W2601471281 cites W2588681363 @default.
• W2601471281 cites W2901368272 @default.
• W2601471281 cites W2921082412 @default.
• W2601471281 cites W4318470725 @default.
• W2601471281 cites W83698396 @default.
• W2601471281 doi "https://doi.org/10.18632/oncotarget.16466" @default.
• W2601471281 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5564654" @default.
• W2601471281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28415634" @default.
• W2601471281 hasPublicationYear "2017" @default.
• W2601471281 type Work @default.
• W2601471281 sameAs 2601471281 @default.
• W2601471281 citedByCount "9" @default.
• W2601471281 countsByYear W26014712812017 @default.
• W2601471281 countsByYear W26014712812018 @default.
• W2601471281 countsByYear W26014712812019 @default.
• W2601471281 countsByYear W26014712812020 @default.
• W2601471281 countsByYear W26014712812021 @default.
• W2601471281 crossrefType "journal-article" @default.
• W2601471281 hasAuthorship W2601471281A5004713760 @default.
• W2601471281 hasAuthorship W2601471281A5036593151 @default.
• W2601471281 hasAuthorship W2601471281A5038304016 @default.
• W2601471281 hasAuthorship W2601471281A5059647160 @default.
• W2601471281 hasAuthorship W2601471281A5090607267 @default.
• W2601471281 hasBestOaLocation W26014712811 @default.
• W2601471281 hasConcept C121608353 @default.
• W2601471281 hasConcept C126322002 @default.
• W2601471281 hasConcept C143998085 @default.
• W2601471281 hasConcept C168563851 @default.
• W2601471281 hasConcept C207103383 @default.
• W2601471281 hasConcept C2776215463 @default.
• W2601471281 hasConcept C2776478404 @default.
• W2601471281 hasConcept C2777176818 @default.
• W2601471281 hasConcept C44249647 @default.
• W2601471281 hasConcept C530470458 @default.
• W2601471281 hasConcept C71924100 @default.
• W2601471281 hasConcept C95190672 @default.
• W2601471281 hasConceptScore W2601471281C121608353 @default.
• W2601471281 hasConceptScore W2601471281C126322002 @default.
• W2601471281 hasConceptScore W2601471281C143998085 @default.
• W2601471281 hasConceptScore W2601471281C168563851 @default.
• W2601471281 hasConceptScore W2601471281C207103383 @default.
• W2601471281 hasConceptScore W2601471281C2776215463 @default.
• W2601471281 hasConceptScore W2601471281C2776478404 @default.
• W2601471281 hasConceptScore W2601471281C2777176818 @default.
• W2601471281 hasConceptScore W2601471281C44249647 @default.
• W2601471281 hasConceptScore W2601471281C530470458 @default.
• W2601471281 hasConceptScore W2601471281C71924100 @default.
• W2601471281 hasConceptScore W2601471281C95190672 @default.

• next